This Podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Interim Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interview Drs. Bob Miller and Carlayne Jackson about the two AAN guidelines on care of patients with amyotrophic lateral sclerosis. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about the smile of Wilson disease. The podcast concludes where Dr. Beau Bruce interviews Dr. Andrew Norden for the Lesson of the Week Drug/Disease segment about VEGF inhibitors. The participants had nothing to disclose except for Drs. Miller and Jackson.Dr. Miller serves on the editorial board of the ALS Journal; received a speaker honorarium from the AANEM; served as a consultant to Celgene, Knopp Neurosciences Inc., Teva Pharmaceutical Industries Ltd., Taiji Biomedical, Inc., Sanofi-aventis, Novartis, and Neuraltus; and receives research support from the NIH [#R01 NS 44887 (PI)] and the Muscular Dystrophy Association (PI).Dr. Jackson serves as a consultant to Knopp Neurosciences Inc.; and receives research support from Knopp Neurosciences Inc., Insmed Inc., Solstice Neurosciences, Inc., the ALS Association, and from the NIH NINDS [#U01 NS042685-0 (Site PI), # R01NS045087-01A2 (Site PI), and # N01-AR-2250 (Site PI)].

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related